Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Phase II Clinical Data going for third party review

<< Previous

Bullboard Posts

Next >>

Post by TheBearInTheWoodson Aug 13, 2021 11:12am

195 Views

Post# 33700605

Phase II Clinical Data going for third party review

Phase II Clinical Data going for third party review

"Arch Biopartners Inc. has provided an update that the analysis of the results of the phase II trial of its lead drug LSALT peptide (metablok) is continuing and will be disclosed to the public following third party, scientific peer review."

ARCH.V - 56% held by insiders

Canadian Innovation Funded Phase II human trial on Organ inflammation

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market